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OR I G I N A L A R T I C L E
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Aims: In the absence of a commonly agreed dosing protocol based on pharmacoki-
netic (PK) considerations, the dose and treatment duration for hydroxychloroquine
(HCQ) in COVID-19 disease currently vary across national guidelines and clinical
study protocols. We have used a model-based approach to explore the relative
impact of alternative dosing regimens proposed in different dosing protocols for
hydroxychloroquine in COVID-19.
Methods: We compared different PK exposures using Monte Carlo simulations based
on a previously published population pharmacokinetic model in patients with rheu-
matoid arthritis, externally validated using both independent data in lupus erythema-
tous patients and recent data in French COVID-19 patients. Clinical efficacy and
safety information from COVID-19 patients treated with HCQ were used to contex-
tualize and assess the actual clinical value of the model predictions.
Results: Literature and observed clinical data confirm the variability in clinical
responses in COVID-19 when treated with the same fixed doses. Confounding fac-
tors were identified that should be taken into account for dose recommendation. For
80% of patients, doses higher than 800 mg day on day 1 followed by 600 mg daily
on following days might not be needed for being cured. Limited adverse drug reac-
tions have been reported so far for this dosing regimen, most often confounded by
co-medications, comorbidities or underlying COVID-19 disease effects.
Conclusion: Our results were clear, indicating the unmet need for characterization of
target PK exposures to inform HCQ dosing optimization in COVID-19. Dosing opti-
mization for HCQ in COVID-19 is still an unmet need. Efforts in this sense are a pre-
requisite for best benefit/risk balance.
K E YWORD S
dosing optimization, dosing rationale, hydroxychloroquine, modelling and simulations,
pharmacokinetics
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1 | BACKGROUND
SARS Coronavirus disease 2019 is the most severe pandemic for
almost a century with more than 1,000,000 infections and 60,000
deaths all over the world within less than 6 months,1 creating an
unprecedented urgent need for an effective and safe drug to stop its
spread and protect populations less skilled to manage the crisis.
Standard drug and vaccine development approaches are lengthy
and expensive: they require years/decades of research and develop-
ment: they are therefore not the optimal response for the current out-
break in view of the rapid spread of the disease. It is therefore
commonly agreed that there is a more pressing need for alternative
solutions, including drug repurposing and modelling and simulations.
Drug repurposing consists in this context of using already
marketed drugs or therapeutics under development for other indica-
tions based on their potential pharmacological interest or the available
non-clinical or clinical data with SARS coronavirus. It can be combined
with alternative evidence generation approaches including modelling
and simulation to address some important questions such as deter-
mining the acceptable dose for the different drugs to be either tested
in clinical trials or implemented in compassionate/off-label use during
the outbreak.
Hydroxychloroquine (HCQ), a 4-aminoquinolein drug approved
and used for decades in the treatment of malaria,2 rheumatoid arthri-
tis3 and cutaneous lupus erythematosus (CLE),4 is being considered as
a potential therapeutic option in COVID-19. Recent in vitro studies
demonstrated the antiviral activity of chloroquine (CQ) and HCQ on
SARS-CoV-2 (see, e.g., Refs. 5, 6 and references therein) with results
showing higher potency (lower in vitro EC50) for HCQ as compared to
CQ, so that lower doses (than in approved indications) could be used
in COVID-19.
HCQ has been used in clinical trials for COVID-19 treatment
with different outcomes/results,7–13 it is currently investigated in a
series of additional ongoing/planned clinical trials,14 and is included
in some national guidelines for management of COVID-19. However,
in the absence of a clear dosing protocol based on drug exposure
in plasma/blood and at the site of infection, dosage and duration
of treatment currently vary across national and clinical study proto-
cols. Inappropriate dosing regimen can lead to an increase risk of
either therapeutic failure or adverse events such as cardiotoxicity
(QT prolongation) and retinopathies.
Modelling and simulation have the potential to optimize the dose
based on the pharmacokinetics (PK) behaviour of the drug, provided that
exposure–response is understood and target concentrations are charac-
terized for both efficacy and safety. It is therefore considered timely to
explore how the evidence gathered with the clinical use of HCQ could
feed the understanding of its PK and PD and inform the dosing in
COVID-19 patients. In March 2020, a physiologically based pharmacoki-
netic (PBPK) model was published by Yao et al. to simulate/predict the
HCQ concentrations in blood, plasma and lung fluid of Chinese patients.5
Based on the PBPK model results, the authors recommend an oral load-
ing dose of 400 mg twice daily of hydroxychloroquine sulfate, followed
by a maintenance dose of 200 mg given twice daily for 4 days However,
no PK data in COVID-19 patients were available to clinically validate the
model. A different and much higher dosing regimen (at least 800 mg daily
over 10 days) has recently been recommended by Garcia-Cremades et al.
based on PK/PD simulation of HCQ effects on SARS COV-2 viral load on
the one hand, and on QT prolonging effects of chloroquine (CQ) (a similar
drug), on the other.15
The first aim of this work is to assess and compare different dosing
regimens using Monte Carlo simulations based on a previously published
population pharmacokinetic (popPK) model in patients with rheumatoid
arthritis (RA),3 externally validated using both independent data in
patients with cutaneous lupus erythematosus (CLE)4 and recent data in
COVID-19 patients.5 Moreover, clinical efficacy and safety information
from COVID-19 patients treated with HCQ at Saint-Pierre hospital
(Brussels, Belgium) and as included in the recently published studies are
used to assess the clinical value of the model predictions.
This work also aims to present and discuss the strength of evi-
dence and the uncertainties for a model-informed approach based on
the currently available data as well as the current gaps in information
for HCQ dose optimization in COVID-19.
2 | METHODS
2.1 | Population pharmacokinetic modelling and
simulation
Two previous published population pharmacokinetic models have
been published for hydroxychloroquine (HCQ) in patients with RA3
What is already known
• Inconsistent doses of hydroxychloroquine are included in
national guidelines and clinical study protocols for man-
agement of COVID-19 disease.
• Modelling and simulation approaches have recently been
proposed for dose selection but (external) clinical valida-
tion was either lacking or carrying important limitations
and unverified assumptions.
Wha this study adds
• We propose a model-based approach for hydro-
xychloroquine dose rationale with clinical validation using
literature pharmacokinetic data in autoimmune disease
and COVID-19.
• Clinical efficacy and safety data in COVID-19 patients
are used for contextualization.
• Uncertainties and gaps are identified as well as data
needed to address them.
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and lupus erythematosus4 using whole-blood HCQ concentrations.
Four additional models describe plasma concentrations or merged
blood and plasma concentrations.16–19 Blood concentrations are
known to be more reproducible (because higher, with lesser analytical
sensitivity issues). We therefore used the model by Carmichael et al.3
for subsequent simulation after independent validation. The authors
developed a one-compartment model with first-order elimination and
absorption and an absorption lag time. Nine of the patients received
oral dose and intravenous infusion for the bioavailability study.
Patients received Plaquenil® tablets, each tablet having 200 mg of
racemic HCQ sulfate equivalent to 155 mg of racemic HCQ base. The
only covariate retained in the model is the methotrexate, a drug most
commonly used in RA.
This model was externally validated using digitized blood con-
centrations obtained from the Morita et al. paper. In this study,
HCQ was used to treat patients with cutaneous lupus
erythematosus.4 The 90 patients received one of these three dosing
regimens of HCQ sulfate, depending on their ideal body weight:
200 mg daily (n = 20), 200 mg and 400 mg every other day
(n = 55), or 400 mg daily (n = 15). The steady-state blood concen-
tration data (three samples per patient) were digitized from figure
1 in the paper by Morita et al.,4 using MATLAB R2016b software
(The MathWorks Inc., Natick City, MA). Monte Carlo simulations
were performed using NONMEM software, version 7.3 (Icon Devel-
opment Solutions, Ellicott City, MD).
This model was also used for simulations of the serum concen-
trations serum PK data including data from 20 patients from the
Gautret et al. study6 with a serum/whole blood correction ratio of
0.53.20 The patients in the Gautret et al. study were confirmed
COVID-19 and received 200 mg every 8 hours for 10 days. It is
assumed that they were trough concentrations, measured before
the first dose of the indicated day. NONMEM software was used
for this purpose.
Subsequently, we used this model to perform simulations of
blood concentrations of HCQ base for different dosing protocols for
treatment of COVID-19. Table 1 includes the relevant information on
the simulations performed. The figures were generated using
MATLAB software.
2.2 | Additional clinical data
In addition to data used for model validation, additional data were
used to get some insight on dose–exposure–response as regards clini-
cally relevant beneficial and toxic effects of HCQ in COVID-19. Even
though these data could not permit a formal exposure–response anal-
ysis, they were used to describe the doses and PK exposure distribu-
tions in COVID-19 patients either with favourable responses
(discharge from the hospital based on criteria described below) or
experiencing adverse drug reactions after treatment with HCQ.
Summary-level and patient-level data were used for this purpose.
i. Summary-level data
These include data from three previously published clinical data in
COVID-19 patients treated either with HCQ monotherapy8,9 or with
HCQ combined with azithromycin (AZM).7,10
ii. Patient-level data
Clinical data were obtained from 172 COVID-19 in-patients hos-
pitalized at Saint-Pierre Hospital in Brussels (Belgium) from 1 March
to 6 April 2020 and treated with HCQ monotherapy. Summary of
patient characteristics as well as relevant information available on
their disease stage and response to HCQ monotherapy are included in
Table 2. Statistical analysis was performed using SAS JMP v.10 soft-
TABLE 1 Hydroxychloroquine sulfate dosing regimens assessed by Monte Carlo simulations
Dosing regimen Loading dose (Day 1) Total loading dose Maintenance dose Total daily dose Duration of treatment
Scenario 0(a) 400 mg BID 800 mg 200 mg BID 400 mg 5 days
400 mg BID 800 mg 200 mg BID 400 mg 10 days
Alternative scenario 0 / / 200 mgTID 600 mg 10 days
Alternative scenario 1 (b) 600 mg BID 1,200 mg 200 mg BID 400 mg 5 days
600 mg BID 1,200 mg 200 mg BID 400 mg 10 days
Alternative scenario 2 (c) 200 mgTID 600 mg 200 mg BID 400 mg 5 days
200 mgTID 600 mg 200 mg BID 400 mg 10 days
Alternative scenario 3 (d) / / 200 mg BID 400 mg 5 days
/ / 200 mg BID 400 mg 10 days
Alternative scenario 4 (e) 400 mg BID 800 mg 400 mg daily 400 mg 5 days
400 mg BID 800 mg 400 mg daily 400 mg 10 days
Alternative scenario 5 (f) 800 mg followed by 400 mg
6 hours later
1,200 mg 200 mg BID 400 mg 5 days
800 mg followed by 400 mg
6 hours later
1,200 mg 200 mg BID 400 mg 10 days
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ware. Criteria for hospitalization included COVID-19 suspicion based
on radiological findings in patients with known severity factors (hyper-
tension, diabetes, lung disease, age >60) and/or with one of the fol-
lowing criteria: oxygen desaturation <94% while breathing ambient
air, respiratory rate > 22/min, heart rate >125, decrease of oxygen
saturation <94% after one minute walking test, altered consciousness.
The following criteria were taken into account before discharge: no
requirement of oxygen supplementation, no evidence of desaturation
while walking without oxygen supplementation, ability of oral medica-
tion intake, and appropriate condition for isolation at home.
Moreover, EudraVigilance (EV), a European public vigilance data-
base including spontaneous reports of adverse events with medica-
tions, was consulted and cases related to the use of HCQ in COVID-
19 extracted.
2.3 | Nomenclature of targets and ligands
Key ligands in this article are hyperlinked to corresponding entries in
http://www.guidetopharmacology.org, the common portal for data
from the IUPHAR/BPS Guide to PHARMACOLOGY.21
3 | RESULTS
The popPK model by Carmichael et al. was successfully replicated as
shown in Figure 1. Results of external validation were satisfactory:
the model by Carmichael was able to acceptably predict previously
published data from external sources in CLE and in COVID-19
patients (see Figure 1).
This model was therefore used to simulate different dosing sce-
narios including in national guidelines and ongoing/planned clinical
study protocols in Belgium. Results of the different simulations are
shown in Figure 2.
Selected clinical response markers including time to discharge
from the hospital, survival, C-reactive protein (CRP), blood oxygen
levels and absolute lymphocyte counts were collected from a cohort
of 172 patients treated with HCQ monotherapy at Saint Pierre Hospi-
tal in Brussels. Summary descriptive statistics are included in Table 2
together with patient age and relevant comorbidities. Most of these
patients received a 5-day treatment scheme with 400 mg BID on day
1 followed by 200 mg BID from days 2 to 5. Three patients received
6 or 7 days of treatment. As regards impact of HCQ treatment on
CRP, blood oxygen levels and absolute lymphocyte counts, while all
the patients received the same dosing regimen for HCQ, variable
responses were observed for each of the biomarkers: a subset had
their levels decreasing (i.e. negative slope) after start of treatment
with HCQ, while others showed an increase in the levels (positive
slope). Moreover, time delay from appearance of symptoms to imple-
mentation of treatment was a significant predictor of admission to the
intensive care unit (p < 0.01, AUC ROC curve = 0.63) and death
(p < 0.01, AUC ROC curve = 0.61) based on logistic regression analy-
sis, while patient age, hypertension, cardiomyopathies, cancer and
obesity were significantly correlated with patient death (p < 0.05).
As regards clinical safety, case reports were found from literature
data and public vigilance database (EV). The dosing regimens informa-
tion was extracted when provided in the report and in most cases
800 mg daily or lower doses were reported for day 1 and
400–600 mg daily were reported for the following days. The time
delay from start of treatment to onset of ADR was very variable (from
1 to several days). Cardiac disorders and especially QT prolongation
were the most frequently reported adverse drug reactions. At least
one of the following additional risk factors was reported in patients
experiencing adverse drug reactions: concomitant medication with at
least one drug known to carry QT prolonging drugs or cardiac toxicity,
relevant comorbidities (e.g. renal impairment), cardiovascular disease,
cardiomyopathies and hypokalaemia (seeTable 2).
4 | DISCUSSION
HCQ is approved and used worldwide for treatment of malaria and
RA (SLE and CLE). The approved doses are higher in magnitude and of
shorter duration in malaria (1,200 mg on day 1 followed by 400 mg
daily over 10 days) as compared to RA (loading dose of 400–800 mg
BID followed by maintenance dose of 200 mg BID chronically with
sometimes therapeutic drug monitoring targeting trough plasma con-
centrations of 0.6-1 mg/L4). Several PK models are available in the lit-
erature for HCQ in these indications.1,2,9 Our choice to use the PK
model by Carmichael et al. was motivated by the fact that it was
TABLE 2 Summary characteristics of patients treated with HCQ






Age (years) 60 [26;96] 172
Gender (males/females) 101/71 172
Time interval from start of
symptoms to start of
treatment (days)
8 [1; 31] 172
Treatment duration (days) 5 [3; 8] 172
Patients in intensive care unit
(yes/no)
40/131 172
Time interval from start of
treatment to discharge from
the hospital (days)
6 [1;18] 172
Death (yes/no) 20/152 172
Diabetes (yes/no) 55/117 172
Hypertension (yes/no) 78/94 172
Cardiomyopathies (yes/no) 34/138 172
Obesity (yes/no) 49/122 172
C-reactive protein (mg/L) 146.1 [2.2; 547.6] 317a
Blood oxygen (%) 92 [23;100] 152a
Absolute lymphocytes (cells/nL) 1.03 [0.16; 8.55] 286a
aSome of the patients had more than one value measured.
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developed to describe a relatively large cohort of blood concentra-
tions (known to be less variable). The estimated apparent clearance
values were quite consistent across previously published popPK
models: 10–11 L/h when whole blood concentrations were
analysed3,4 vs 51–68 L/h when plasma concentrations were
analysed.16–19 The predictive performance of the Carmichael et al.
model was confirmed on external data including data in CLE patients
and in COVID-19 patients with overall satisfactory fitting of digitized
concentrations. It is therefore judged adequate to be used for explor-
ing the differential/relative impact of alternative dosing regimens in
COVID-19 patients in the absence of a refined popPK model devel-
oped using COVID-19 patient data. It should, however, be noted that
this model still carries an high unexplained variability component on
the volume of distribution and clearance parameters: there is there-
fore a need for refinement of this model and better characterization
of PK in COVID-19 patients, including by adequate description of
F IGURE 1 Model validation. (A) Prediction of Carmichael et al. PK data (200 mg daily). Blue line: Median. Black lines: 2.5 and 97.5 percentiles
(95% prediction interval). Red circles: Observed (blood) concentrations in RA patients digitized from Carmichael et al. publication.3 (B-E)
Prediction of Morita et al. PK data for different dosing regimens: (b) 200 mg daily, (c) 200 or 400 mg every other day, when the last dosing just
before blood sampling is 200 mg, (d) 200 or 400 mg every other day, when the last dosing just before blood sampling is 400 mg, (e) 400 mg daily.
Blue line: Medians. Black lines: 2.5 and 97.5 percentiles (95% prediction intervals). Red circles: Observed (blood) concentrations in CLE patients
digitized from Morita et al. publication.4 (F) Prediction of Gautret et al. PK data (200 mgTID for 10 days). Blue line: Median. Black lines: 2.5 and
97.5 percentiles (95% prediction interval). Circles: Observed corrected serum concentrations in COVID-19 patients from Gautret et al.
publication6 (blue/black refers to PCR-negative patients on day 6, red refers to PCR-positive patients on day 6, black refers to patients with
azithromycin added to HCQ treatment)
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covariate effects. Potential covariates include bodyweight, CYP2D6
modulators and underlying renal impairment.
In the absence of a high loading dose, the results of the dos-
ing simulation scenarios show that the drug progressively accumu-
lates over the dosing periods of 5 or 10 days: safety monitoring
can therefore be needed throughout the dosing period and even
after. This is confirmed by case reports of patients experiencing
adverse drug reactions such as QT prolongation even after drug
withdrawal. The appropriate characterization of the loading and
maintenance doses needed is therefore important not only for drug
efficacy but also for drug safety. The use of high loading doses
needs to be justified in view of the hazard for serious adverse
events. There is still uncertainty on the target/relevant systemic
concentrations for drug efficacy and safety. This is an important
gap to be filled in the current situation because systemic concen-
trations are more accessible for monitoring than could be lung con-
centrations. There is an unmet need for adequately conducted
clinical PK and exposure–response studies.
The antiviral action of HCQ is possibly the result of its cationic
amphiphilic properties.22 Hydroxychloroquine is metabolized to
F IGURE 2 Simulated blood PK profiles for different dosing regimens: (A) 400 mg BID on day 1 followed by 200 mg BID (Belgian protocol),
(B) 600 mg BID on day 1 followed by 200 mg BID, (C) 200 mg TID on day 1 followed by 200 mg BID, (D) no loading dose, 200 mg BID, (E)
400 mg BID on day 1 followed by 400 mg daily, (F) 800 mg and 400 mg 6 hours later on day 1, followed by 200 mg BID. Blue lines: Medians.
Black lines: 5th and 95th percentiles (90% prediction intervals). Solid lines: Treatment for 10 days. Dotted lines: Treatment for 5 days. The
green and purple horizontal lines represent the projected target total whole blood concentrations based on EC50 values from Yao et al. [ref] and
Liu et al. [red], respectively
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desethylhydroxychloroquine, which is also a cationic amphiphilic
molecule, and might also carry some antiviral effects, even if this
effect has not been tested/reported so far. An additive effect
due to desethylhydroxyquine remains theoretically possible. Interest-
ingly, Munster et al.23 reported PK of hydroxychloroquine and
desethylhydroxychloroquine with concentrations measured in the
same patients: the PK curves were shown to be parallel with similar
time to maximum concentrations and elimination half-life for HCQ
and desethylhydroxychloroquine and much higher parent drug con-
centrations (ratios around 1.75:1). The strong correlation could
therefore justify that hydroxychloroquine concentrations are also
informative for desethylhydroxychloroquine concentrations in the
same patient. Our results are therefore informative for drug effects
even in the absence of analysis of potential metabolite effects.
Yao et al.5 have shown in their recent publication that in vitro
EC50 for prophylactic and treatment antiviral effects on SARS COV-2
were 0.72 and 5.85 μM, respectively, while higher EC50 values have
also been reported for HCQ by other research groups (e.g. 4.51 μM
for MOI 0.01 by Liu et al.24). For graphical comparative purposes,
EC50 values by Yao et al.
5 and Liu et al.,24 scaled to whole blood con-
centrations (assuming no protein binding in the in vitro setting and
50% protein binding in patients), are included in Figure 2. It should be
noted that, for most of the dosing regimen proposed, the simulated
concentrations are below the concentrations needed for relevant ant-
iviral effects of HCQ. It should also be noted that the immunomodula-
tory effects of hydroxychloroquine could also contribute to the
overall clinical effects in addition to the potential antiviral effects.
Characterizing the PK/PD and exposure–response is beyond the
scope of our paper. However, it is believed that these different effects
are linked to HCQ concentrations.
Based on a PBPK modelling approach Yao et al. have proposed
dosing regimens that allow reaching empirically determined ratios
between free lung concentrations and the in vitro EC50. However, in
addition to the fact that this model was not validated using clinical
data in COVID-19 patients, the recommended doses should still be
cautiously considered because the relevant target ratios between lung
or systemic concentrations and in vitro active levels are still to be
established as well as the ranges for effective whole blood and plasma
total concentrations. A more recent paper15 was published in this
sense using a model-based approach and PK/PD modelling of viral
load and QT prolongation. However, it should be noted that this was
a retrospective analysis of either aggregated or limited previously
published data generated in different settings and for different
purposes. Several unverified assumptions were therefore needed
for the PK/viral load and the PK/QT modelling. Of note, the
assumed/modelled QT prolonging effects were those of choloroquine
and not hydroxychloroquine. Moreover, the overall unexplained vari-
ability was very high and covariate modelling was not implemented.
Research is still needed to determine target HCQ level for in vivo
(human) antiviral effect in COVID-19 and the link with clinically rele-
vant outcomes such as patient cure and survival for the different dis-
ease stages. Given the known multiphasic features of the COVID-19
disease and the importance of the inflammatory component of the
disease, it is still unclear how relevant viral load clearance by antiviral
drugs are for the patient clinical outcomes in early vs later stages of
the disease.
While it is not possible to identify the optimal dose in the absence
of properly conducted dose–exposure–response analyses using rele-
vant data in the target indication, the currently available clinical effi-
cacy and safety data in different doses used in COVID-19 patients
can already provide some useful information on the dose requirement
when interpreted together with the related PK information. High rates
of positive clinical outcomes have been reported with doses of
600–800 mg daily on day 1 followed by 400–600 mg daily for a total
treatment duration of 5–10 days,6–10 also confirmed in the cohort of
172 patients treated at Saint Pierre hospital (see Table 2 and
Figure 3). While these studies were all either single arm (no placebo
arm), uncontrolled or of limited size, and therefore precluding the
robust identification of the actual drug effect size, the important
learning from these data is that higher doses might not be needed for
an important proportion of patients. The determinants of positive
patient outcomes are still to be identified, and HCQ dose optimization
can certainly be one of them. Additionally, as extensively discussed in
the recent literature, disease stage, patient age and comorbidities
might also play key roles.25–27
As regards safety, the overall safety profile seems quite good
when the drug is given at a dose of 400–800 mg on day 1 followed by
400–600 mg daily for 5 to 10 days, under close clinical monitoring.
Available concerning cases reported in EV or in the literature are con-
sistent with the known safety concerns with HCQ. Aggravation of the
toxicity due to comorbidities or underlying renal or liver diseases
related to COVID-19 pathophysiology cannot be excluded either25–27
(see also Table 3). It is therefore essential that patients treated with
HCQ are closely monitored for these risk factors, and that appropriate
risk minimization measures are implemented as needed.
It should, however, be noted that the clinical safety data from EV
should be interpreted cautiously due to the potential bias related to
spontaneous underreporting.
F IGURE 3 Histogram of times to discharge for patients of Saint
Pierre hospital
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5 | CONCLUSION
We have successfully used a model-based approach to explore the
relative impact of alternative dosing regimens proposed in different
dosing protocols for HCQ.
It was clear from our results that there is an unmet need for
adequate characterization of target PK exposures in COVID-19
patients to inform the dosing optimization. Literature data and clin-
ical data from a Belgian hospital confirm the variability in clinical
responses when the same fixed doses are given to all patients.
Some confounding factors were identified that should be taken
into account for dose recommendation. For 80% of patients in the
Saint Pierre cohort, doses higher than 600–800 mg daily on day
1 followed by 400–600 mg daily on following days might not be
needed for positive outcome. Very limited ADRs have been
reported so far for this dosing regimen; moreover, they were most
often confounded by co-medications, comorbidities or underlying
disease effects.
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